European Off-Patent Industry Decries Price Cuts And Clawbacks
Medicines for Europe Calls For Pricing And Reimbursement Reform
A Medicines for Europe report on policies affecting the off-patent industry across 22 European countries aims to demonstrate the urgent need for pricing and reimbursement and procurement reforms.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
A European Medicines Agency pilot scheme offering tailored scientific advice on biosimilar development has been viewed by applicants as a “valuable opportunity” and the process will continue as part of regular operations, according to an agency report.
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.